Onconetix Schedules Special Meeting for New Reverse Stock Split Authority Amid Ongoing Nasdaq Compliance Challenges
ONCO is trading near its 52-week low of $1.78 (16% below the low) on elevated volume (59× avg).
Summary
Onconetix filed a definitive proxy statement for a special meeting on April 30, 2026, seeking shareholder approval for new discretionary authority to implement further reverse stock splits, up to an aggregate of 1-for-100, to maintain Nasdaq listing compliance.
Key Events · Corporate Governance and Compliance · ONCO
-
Special Meeting Scheduled for Reverse Stock Split Vote
Onconetix will hold a special meeting on April 30, 2026, for stockholders to vote on granting the Board discretionary authority to effect one or more reverse stock splits.
-
New Reverse Stock Split Authority Sought
The Board is requesting authority for reverse stock splits in a range of 1-for-2 to 1-for-10, with an aggregate limit of 1-for-100, to be implemented within one year.
-
Ongoing Nasdaq Compliance Issues
This proposal is a direct response to persistent Nasdaq listing challenges, following a 1-for-85 reverse split in June 2025 and a 1-for-5 reverse split effective March 25, 2026.
-
Impact on Capital Raising and Liquidity
The company emphasizes that maintaining Nasdaq listing through reverse splits is crucial for capital raising activities and preventing a decline in stock liquidity, especially given its 'going concern' warning.
Analysis · ONCO · Life Sciences
Onconetix, a micro-cap company facing significant financial distress and a going concern warning, has filed a definitive proxy statement to seek shareholder approval for additional reverse stock split authority. This proposal, allowing for splits ranging from 1-for-2 to 1-for-10 (up to an aggregate of 1-for-100), is a critical measure to maintain Nasdaq listing compliance. The need for repeated reverse splits, following a 1-for-85 split in June 2025 and a 1-for-5 split just last week, highlights the company's persistent struggle to meet minimum bid price requirements. While necessary for continued listing and access to capital, this continuous dilution and reliance on reverse splits signal deep-seated operational and financial challenges. Investors should monitor the outcome of the April 30, 2026, special meeting and the company's ability to sustain its stock price above Nasdaq's minimum threshold.
At the time of this filing, ONCO was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $1.78 to $74.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.